The global autoinjectors market is projected to grow at an annualized rate of ~10% and be worth around USD 2.5 Billion, till 2030
Roots Analysis has done a detailedstudy on GlobalAutoinjectors Market (3rdEdition), 2020-2030, covering key aspects of the industry’s evolution andidentifying potential future growth opportunities.
To order this 600+page report, which features 360+ figures and 350+ tables, please visit this https://www.rootsanalysis.com/reports/view_document/autoinjectors-market/293.html
Key Market Insights
§ Currently, several companies claim to be engaged in the development/ manufacturing of various types of autoinjectors, most of which are disposablesystems that use prefilled syringes as primary drug containers
§ About 90autoinjector-based combination products have been approved for the treatment ofa variety of clinical conditions; the subcutaneous route being the preferredmode of drug delivery via such devices
§ In order to gain a competitive edge in themarket, many autoinjector manufacturers are focusing on the integration ofadvanced features into their respective products and affiliated offerings
§ Over time, more than 4,600 patents have beenfiled / granted related to autoinjectors and affiliated products; most of thenew intellectual property is related to additional features, such as safetylocks and device connectivity
§ Eminent scientists fromrenowned organizations and academic institutions across the world have madevaluable contributions to this field, in terms of leading clinical researchefforts and developing novel technologies
§ Several autoinjector developershave established strong brand positions in different geographies; the focus, inthe near term, is likely to be on further enhancing device features for betterdisease management and improved patient compliance
§ An evaluation of 200+marketed and pipeline products revealed that a variety of drugs / productcandidates are likely to be considered for administration via autoinjectors inthe near future
§ Case Study: Owing to the complexitiesassociated with the manufacturing and assembly of autoinjector drug deliverysystems, industry players are known to frequently engage the services ofcontract service providers
§ Currently, disposableautoinjector products for small molecule drugs dominate the market; however, inthe foreseen future, the demand for reusable devices is anticipated to witnesssignificant growth
§ Given the recentapprovals and presence of multiple drug candidates in later stages ofdevelopment, the market opportunity is likely to be distributed acrossdifferent therapeutic areas, routes of administration and geographies
For more information, please visit https://www.rootsanalysis.com/reports/view_document/autoinjectors-market/293.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Drug Delivery Systems
3.3. Drawbacks of Conventional ParenteralDelivery Systems
3.4. Needlestick Injuries
3.4.1. Incidence and Cost Burden
3.4.2. Government Legislation for thePrevention of Needlestick Injuries
3.5. Emerging Trend of Self-Administration
3.5.1. Rising Burden of Chronic Diseases
3.5.2. Healthcare Cost Savings
3.5.3. Need for Immediate Treatment inEmergency Situations
3.5.4. Growth of Injectable Biologics Market
3.5.5. Addressing Key User Safety Requirements
3.6. Types of Self- Administration Devices
3.6.1. Prefilled Syringes
3.6.2. Pen-Injectors
3.6.3. Needle-Free Injectors
3.6.4. Autoinjectors
3.6.5. Large Volume Wearable Injectors
3.7. Overview of Autoinjectors
3.7.1. Components of Autoinjectors
3.7.2. Classification of Autoinjectors
3.7.2.1. On the Basis of Mechanism of Action
3.7.2.2. On the Basis of Usability
3.7.2.3. On the Basis of Type of Dose
3.7.3. Manufacturing / Packaging ofAutoinjectors
3.7.4. Benefits of Autoinjectors
3.8. Regulatory Considerations
3.8.1. Medical Devices
3.8.2. Drug Device Combination Products
3.9. Future Perspectives
4. PRIMARY DRUG CONTAINERS
4.1. Chapter Overview
4.2. Types of Packaging
4.3. Introduction to Primary DrugContainers
4.3.1. Role of Primary Drug Containers
4.3.2. Types of Primary Drug Containers
4.3.2.1. Cartridges
4.3.2.1.1. Components of Cartridges
4.3.2.1.2. Types of Cartridges
4.3.2.1.2.1. Single Chamber Cartridge
4.3.2.1.2.2. Dual Chamber Cartridge
4.3.2.1.3. Cartridges Available in the Market
4.3.2.2. Syringes
4.3.2.2.1. Components
4.3.2.2.2. Types of Syringes
4.3.2.2.2.1. Based on Number of Chambers
4.3.2.2.2.2. Based on Type of Needle
4.3.2.2.3. Prefilled Syringe Systems Available in theMarket
4.3.2.2.3.1. Glass Prefilled Syringes
4.3.2.2.3.2. Plastic Prefilled Syringes
4.3.2.3. Vials
4.3.2.3.1. Components
4.3.2.3.2. Vials Available in the Market
4.4. Comparison of Fabrication Materials
5. AUTOINJECTORS: CURRENT MARKETLANDSCAPE
5.1. Chapter Overview
5.2. Autoinjectors: List of Devices
5.2.1. Analysis by Usability
5.2.2. Analysis by Type of Primary Container
5.3. Autoinjectors: List of AdditionalParameters of Devices
5.3.1. Analysis by Volume of Container
5.3.2. Analysis by Type of Dose
5.3.3. Analysis by Route of Administration
5.3.4. Analysis by Actuation Mechanism
5.3.5. Analysis by Type of Feedback Mechanism
5.4. Autoinjectors: List of Developers
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size
5.4.3. Analysis by Geographical Location ofHeadquarters
6. PRODUCT COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Assumptions and Key Parameters
6.4. Product Competitiveness Analysis
6.4.1. Disposable Autoinjectors
6.4.2. Reusable Autoinjectors
7. BRAND POSITIONING ANALYSIS OF KEYINDUSTRY PLAYERS
7.1 Chapter Overview
7.2. Scope and Methodology
7.3. Brand Positioning Matrix: AntaresPharma
7.4. Brand Positioning Matrix: BD
7.5. Brand Positioning Matrix: DALIMedical Devices
7.6. Brand Positioning Matrix: Elcam DrugDelivery Devices
7.7. Brand Positioning Matrix: OvalMedical Technologies
7.8 Brand Positioning Matrix: OwenMumford
7.9. Brand Positioning Matrix: SHL Medical
7.10 Brand Positioning Matrix: Union Medico
7.11. Brand Positioning Matrix: Ypsomed
8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Autoinjectors: Patent Analysis
8.3.1. Analysis by Application Year
8.3.2. Analysis by Issuing Authority
8.3.3. Analysis by CPC Symbols
8.4. Emerging Areas
8.5. Leading Players Based on Number ofPatents
8.6. Autoinjectors: Patent BenchmarkingAnalysis
8.6.1. Analysis by Patent Characteristics
8.6.2. Analysis by Geography
8.7. Autoinjectors: Patent ValuationAnalysis
9. THERAPEUTIC PRODUCTS AVAILABLE INAUTOINJECTORS
9.1. Chapter Overview
9.2. Autoinjector Combination Products:List of Approved Drugs
9.2.1. Analysis by Initial Year of Approval
9.2.2. Analysis by Usability
9.2.3. Analysis by Route of Administration
9.2.4. Analysis by Primary Drug Container
9.3. Approved Autoinjector CombinationProducts: List of Additional Parameters
9.3.1. Analysis by Type of Molecule
9.3.2. Analysis by Dose Strength
9.3.3. Analysis by Therapeutic Indication
9.3.4. Analysis by Other Packaging Formats ofMarketed Drugs
9.4. Autoinjector Combination Products:List of Pipeline Drugs
9.4.1. Analysis by Phase of Development
9.5. Pipeline Autoinjector CombinationProducts: List of Additional Parameters
9.5.1. Analysis by Route of Administration
9.5.2. Analysis by Type of Molecule
9.5.3. Analysis by Therapeutic Indication
9.5.4. Grid Analysis: Distribution by TherapeuticIndication, Phase of Development and Route of Administration
9.6. Autoinjector Combination Products:List of Developers
9.6.1. Analysis by Year of Establishment
9.6.2. Analysis by Company Size
9.6.3. Analysis by Location of Headquarters
10. CASE STUDY: AUTOINJECTOR-BASEDCOMBINATION PRODUCTS AND AFFILIATED THERAPEUTIC AREAS
10.1. Chapter Overview
10.2. Marketed / Pipeline Drugs BeingEvaluated with Autoinjectors
10.3. Case Study I: Anaphylaxis
10.3.1. Overview and Epidemiology
10.3.2. Adrenaline: Mechanism of Action
10.3.3. History of Development
10.3.4. Marketed Adrenaline / EpinephrineAutoinjectors
10.3.4.1. Adrenaclick
10.3.4.2. Allerject / Auvi-Q (Formerly called e-cue)
10.3.4.3. Anapen
10.3.4.4. Emerade
10.3.4.5. EpiPen / EpiPen Jr
10.3.4.6. Jext
10.3.4.7. EpiPen / EpiPen Jr
10.3.5. Adrenaline / Epinephrine AutoinjectorsUnder Development
10.3.5.1. EpiQ
10.3.5.2. ANDIPen
10.3.5.3. MiniEpi
10.3.5.4. Zeneo Adrenaline
10.3.6. Other Dosage Forms
10.3.7. Historical Sales of Approved Drugs /Autoinjectors
10.4. Case Study II: Multiple Sclerosis
10.4.1. Overview and Epidemiology
10.4.2. Interferon β-1a
10.4.3. Interferon β-1b
10.4.4. Interferons: Mechanism of Action
10.4.5. History of Development
10.4.6. Interferon β-1a Autoinjectors
10.4.6.1. Avonex Pen
10.4.6.2. PLEGRIDY Pen
10.4.6.3. Rebif Rebidose
10.4.6.4. RebiSmart
10.4.6.5. Rebiject II
10.4.6.6. ReciGen Physioject
10.4.7. Interferon β-1b Autoinjectors
10.4.7.1. BETACONNECT
10.4.7.2. BETAJECT Comfort / Betacomfort
10.4.7.3. Betaject Lite
10.4.7.4. ExtaviJect 30G / ExtaviPro 30G
10.4.8. Other Marketed Autoinjectors
10.4.8.1. Cinnomer40 Physioject
10.4.8.2. CSYNC Autoinjector
10.4.8.3. WhisperJECT
10.4.8.4. Remurel Autoxon
10.4.9. Other Dosage Forms
10.4.10. Historical Sales of Approved Drugs /Autoinjectors
10.4.10.1. Interferon β-1a
10.4.10.2. Interferon β-1b
10.5. Case Study III: Migraine
10.5.1. Overview and Epidemiology
10.5.2. Sumatriptan Succinate: Mechanism ofAction
10.5.3. History of Development
10.5.4. Marketed Autoinjectors
10.5.4.1. ALSUMA
10.5.4.2. IMITREX STATdose Pen
10.5.4.3. Zembrace SymTouch
10.5.4.4. Aimovig SureClick Autoinjector
10.5.4.5. Emgality Prefilled Pen
10.5.5. Other Dosage Forms
10.5.6. Historical Sales of Approved Drugs /Autoinjectors
10.6. Case Study IV: Rheumatoid Arthritis
10.6.1. Overview and Epidemiology
10.6.2. History of Development
10.6.3. Marketed Autoinjectors for RheumatoidArthritis
10.6.3.1. Actemra
10.6.3.2. CIMZIA AutoClicks Prefilled Pen
10.6.3.3. Enbrel SureClick
10.6.3.4. Hulio Prefilled Pen
10.6.3.5. HUMIRA Pen
10.6.3.6. ORENCIA ClickJect
10.6.3.7. OTREXUP
10.6.3.8. Rasuvo Autoinjector
10.6.3.9. SIMPONI SmartJect Autoinjector
10.6.3.10. KEVZARA Prefilled Pen
10.6.3.11. IMRALDI Prefilled Pen
10.6.4. Historical Sales of Approved Drugs /Autoinjectors
11. LIKELY DRUG CANDIDATES FOR DELIVERYVIA AUTOINJECTORS
11.1. Chapter Overview
11.2. Methodology and Key Parameters
11.3. Marketed Drug Candidates for Deliveryvia Autoinjectors
11.3.1. Most Likely Drug Candidates
11.3.2. Likely Drug Candidates
11.3.3. Less Likely Drug Candidates
11.3.4. Unlikely Drug Candidates
11.4. Clinical Drug Candidates for Deliveryvia Autoinjectors
11.4.1. Most Likely Drug Candidates
11.4.2. Likely Drug Candidates
11.4.3. Less Likely Drug Candidates
11.4.4. Unlikely Drug Candidates
12. KEY PLAYERS
12.1. Chapter Overview
12.2. Antares Pharma
12.2.1. Company Overview
12.2.2. Financial Information
12.2.3. Product Portfolio
12.2.3.1. Autoinjectors: Product Details
12.2.3.1.1. Vibex
12.2.3.1.2. QuickShot
12.2.3.1.3. BigShot
12.2.4. Collaborators
12.2.4.1. Teva Pharmaceutical
12.2.4.2. Ferring Pharmaceuticals
12.2.4.3. AMAG Pharmaceuticals
12.2.4.4. JCR Pharmaceuticals
12.2.4.5. Pfizer
12.2.4.6. Idorsia Pharmaceuticals
12.2.5. Recent Developments and Future Outlook
12.3 Consort Medical (Previously Bespak)
12.3.1. Company Overview
12.3.2. Financial Information
12.3.3. Technology Overview
12.3.4. Product Portfolio
12.3.4.1. Autoinjectors: Product Details
12.3.4.1.1. Syrina
12.3.4.1.2. OTS Autoinjector
12.3.4.1.3. Viscala Autoinjector
12.3.5. Collaborators
12.3.5.1. Aesica Pharmaceuticals
12.3.5.2. Undisclosed Global Biopharmaceutical Company
12.3.5.3. Regeneron Pharmaceuticals
12.3.6. Recent Developments and Future Outlook
12.4. DALI Medical Devices
12.4.1. Company Overview
12.4.2. Product Portfolio
12.4.2.1. Autoinjectors: Product Details
12.4.2.1.1. SAN-L
12.4.2.1.2. SAN-P
12.4.2.1.3. SAN-DV
12.4.2.1.4. SAN-DV Pro
12.2.2.1.5. SAN-Light
12.4.3. Collaborators
12.4.3.1. Elcam Drug Delivery Devices
12.4.4. Recent Developments and Future Outlook
12.5. Elcam Medical (E3D Elcam Drug DeliveryDevices)
12.5.1. Company Overview
12.5.2. Product Portfolio
12.5.2.1. Autoinjectors: Product Details
12.5.2.1.1. Flexi-Q Disposable Autoinjectors
12.5.2.1.1.1. Flexi-Q PFS
12.5.2.1.1.2. Flexi-Q HV
12.5.2.1.1.3. Flexi -Q DV
12.5.2.1.2. Flexi-Q Reusable Autoinjectors
12.5.2.1.2.1. Flexi-Q mMU
12.5.2.1.2.2. Flexi-Q eMU-C / P
12.5.2.1.2.3. Flexi-Q EAI
12.5.3. Comparison of Elcam Medical Autoinjectors
12.5.4. Collaborators
12.5.4.1. DALI Medical Devices
12.5.5. Recent Developments and Future Outlook
12.6. Jiangsu Delfu Medical Devices
12.6.1. Company Overview
12.6.2. Financial Information
12.6.3. Product Portfolio
12.6.3.1. Autoinjectors: Overview and Specifications
12.6.3.1.1. Components of Delfu Autoinjectors
12.6.3.1.2. Applications of Delfu Autoinjectors
12.6.3.1.3. Features of Delfu Autoinjectors
12.6.3.1.4. Advantages of Delfu Autoinjectors
12.6.3.1.5. Specifications of Delfu Autoinjectors
12.6.3.2. Autoinjectors: Product Details
12.6.3.2.1. YZ-II 3mL Cartridge Digital Dose Setting GFAutoinjector
12.6.3.2.2. DZ-IA 3 mL Cartridge Needle Hidden VaccinationAutoinjector
12.6.3.2.3. DZ-IA Auto Injector Pen
12.6.3.2.4. Intravitreal Anti-VEGF Injections ElectricInsulin Pens
12.6.3.2.5. YZ-III Standard 3 mL Cartridge ReusableElectronic Auto Injector Pen
12.6.3.2.6. YZ-III 0.001mL Dose Increments Fully AutomatedReusable Injectors
12.6.3.2.7. YZ-III 0.001 mL Dose Accuracy Auto Injector Pen
12.6.3.2.8. YZ-II 3mL* 1u Auto Injector Pen
12.6.3.2.9. YZ-V 3 mL Cartridge Replaceable Variable-doseClassic Auto Injector Pen
12.6.3.2.10. YZ-III Automatic Reusable Insulin Injection Pen
12.6.4. Recent Developments and Future Outlook
12.7. Oval Medical Technologies
12.7.1. Company Overview
12.7.2. Product Portfolio
12.7.2.1. Autoinjectors: Product Details
12.7.2.1.1 ArQ
12.7.2.1.2 ArQ - Bios
12.7.2.1.3 ArQ - Tempo
12.7.2.1.4 ArQ - Vita
12.7.3. Collaborators
12.7.3.1. SOLIZE
12.7.4. Recent Developments and Future Outlook
12.8. Owen Mumford
12.8.1. Company Overview
12.8.2. Product Portfolio
12.8.2.1. Autoinjectors: Product Details
12.8.2.1.1. Autoject Micro
12.8.2.1.2. Autoject 2
12.8.2.1.3. Autoject Mini
12.8.2.1.4. Autoject Visco
12.8.2.1.5. UniSafe Auto-injector
12.8.2.1.6. UniSafe Connected Auto-injector
12.8.3. Collaborators
12.8.3.1. Nipro
12.8.3.2. Sanofi Aventis
12.8.4. Recent Developments and Future Outlook
12.9. SHL Group
12.9.1. Company Overview
12.9.2. Product Portfolio
12.9.2.1. Two-Step Disposable Autoinjectors: ProductDetails
12.9.2.1.1 Amber (Pushclick Technology)
12.9.2.1.2. Molly
12.9.2.1.3. Molly RNS
12.9.2.1.4. Molly 2.25
12.9.2.1.5. Rotaject
12.9.2.1.6. Bertha
12.9.2.1.7. DAI 2
12.9.2.1.8. Maggie
12.9.2.1.9. Comparison of SHL Two-Step Autoinjectors
12.9.2.2. Three-Step Disposable Autoinjectors: ProductDetails
12.9.2.2.1. DAI
12.9.2.2.2. SDI-MIX+NIT (Needle Isolation Technology andTwist and Mix Mechanism)
12.9.2.2.3. VSDI+NIT
12.9.2.2.4. Comparison of SHL Three-Step Autoinjectors
12.9.2.3. PPI Injector (Rotaject Pressure ReleaseTechnology)
12.9.4. Collaborators
12.9.4.1. Schreiner MediPharm
12.9.4.2. QuiO
12.9.5. Recent Developments and Future Outlook
12.10. Union Medico
12.10.1. Company Overview
12.10.2. Technology Overview
12.10.3. Product Portfolio
12.10.3.1. Autoinjectors: Product Details
12.10.3.1.1 45˚ Autoinjector
12.10.3.1.2 45˚/ S Autoinjector
12.10.3.1.3 45˚/ M Autoinjector
12.10.3.1.4 45˚/ R Autoinjector
12.10.3.1.5 Comparison of 45˚ Autoinjectors
12.10.3.1.6 90˚Autoinjector
12.10.3.1.7 90˚/ S Autoinjector
12.10.3.1.8 90˚/ M Autoinjector
12.10.3.1.9 90˚/ XL Autoinjector
12.10.3.1.10 SuperGrip Autoinjector
12.10.3.1.11 Exclusive Autoinjector
